In a separate Phase I clinical trial (NCT01346358), LY3022855 induced a tumor-localized reduction in CD68+ and CD163+ macrophage levels in patients with solid tumors, including melanoma, as confirmed by histological analysis of biopsies. This evidence concerns the gene CD163 and neoplasm.